ContraVir Pharmaceuticals Inc (CTRV) Shares Up 10.2%

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) shot up 10.2% during mid-day trading on Friday . The company traded as high as $0.64 and last traded at $0.62. 1,018,388 shares traded hands during trading, a decline of 11% from the average session volume of 1,139,970 shares. The stock had previously closed at $0.56.

Separately, Maxim Group set a $4.00 target price on ContraVir Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 19th.

The company’s market cap is $48.13 million. The firm’s 50-day moving average is $0.58 and its 200-day moving average is $0.67.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the period. Vanguard Group Inc. owned about 3.79% of ContraVir Pharmaceuticals worth $1,400,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2017/10/29/contravir-pharmaceuticals-inc-ctrv-shares-up-10-2.html.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

What are top analysts saying about ContraVir Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ContraVir Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit